Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs Sana Biotechnology Inc (SANA) Price & Performance

YieldMax AMZN Option Income Strategy ETFTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

YieldMax AMZN Option Income Strategy ETF vs Sana Biotechnology Inc — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $10.75, while Sana Biotechnology Inc trades at $3.8 (market cap $1.07B). The key difference: Sana Biotechnology Inc is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

AMZYSANA
Sector
Income / Options OverlayHealth
52-Week High
$16.61$5.92
52-Week Low
$10.26$2.68
Market Cap
$1.07B
Enterprise Value
$1.04B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax AMZN Option Income Strategy ETF

AMZY trades at $10.78 with no significant daily movement, showing neutral technical signals overall. The ETF maintains a consistent weekly dividend distribution strategy, though recent analyst commentary highlights concerns about NAV erosion despite high yields. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance levels cluster tightly around $10-11.

The outlook remains cautious as the synthetic option strategy delivers high income but exposes investors to amplified downside risk. While weekly distributions provide income appeal, total returns have lagged the underlying Amazon stock, creating sustainability concerns for long-term investors seeking both income and capital appreciation.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.85, down 2.04% today, with a bullish technical outlook from moving averages but overbought RSI signals. The company shows significant losses with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve in 2026. Recent news highlights clinical data presentations and a $69M stock sale via ATM facility in May 2026.

Despite heavy losses, analyst sentiment is strongly bullish with 82% buy ratings, reflecting optimism for SANA's engineered cell therapies. Key risks include sustained cash burn and clinical trial outcomes. The stock's appeal hinges on pipeline success, making it suitable for risk-tolerant investors betting on biotech innovation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About YieldMax AMZN Option Income Strategy ETF

AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.

Read more on AMZY

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA